FOLFIRINOX Induction Chemotherapy for Synchronous Liver Metastases
Recruiting
Observational Study
Rectal Cancer
Synchronous Liver Metastases
Antineoplastic Combined Chemotherapy Protocols
Surgical Therapy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 550 (estimated)
- Sponsor
- Assistance Publique - Hôpitaux de Paris · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
SYNCHRONOX is a multicenter cohort (retrospective then prospective) intending to include 550 patients with mid or low rectal adenocarcinoma (pMMR, T3-T4 and/or N+) and resectable synchronous liver metastases, treated upfront with at least two cycles of induction FOLFIRINOX chemotherapy. The primary objective is to determine, at 18 months, the R0 resection rate of both tumor sites (rectum and liver…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adult subjects aged 18 years and older
* Adenocarcinoma of the middle and/or lower rectum pMMR T3, T4, and/or N+
* Resectable synchronous liver metastases
Exclusion Criteria:
* Minor under the age of 18.
* Presence of extrahepatic metastases
* Induction chemotherapy with FOL…
Contacts